Vivos Therapeutics (NASDAQ:VVOS) Major Shareholder Michael Skaff Purchases 1,353,625 Shares

Vivos Therapeutics, Inc. (NASDAQ:VVOS) major shareholder Michael Skaff bought 1,353,625 shares of the company’s stock in a transaction on Tuesday, March 31st. The stock was bought at an average cost of $1.34 per share, with a total value of $1,813,857.50. Following the completion of the purchase, the insider owned 1,353,625 shares of the company’s stock, valued at approximately $1,813,857.50. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Vivos Therapeutics Price Performance

VVOS opened at $1.32 on Friday. Vivos Therapeutics, Inc. has a one year low of $1.09 and a one year high of $7.95. The company has a debt-to-equity ratio of 3.31, a current ratio of 0.78 and a quick ratio of 0.78. The company’s 50 day simple moving average is $1.44 and its 200-day simple moving average is $2.14. The stock has a market capitalization of $13.82 million, a P/E ratio of -0.75 and a beta of 6.93.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Wednesday, January 21st. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $4.92.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of VVOS. Acorn Wealth Advisors LLC bought a new stake in shares of Vivos Therapeutics during the fourth quarter worth approximately $30,000. XTX Topco Ltd acquired a new position in Vivos Therapeutics in the second quarter valued at approximately $65,000. B. Riley Wealth Advisors Inc. bought a new position in Vivos Therapeutics in the second quarter valued at approximately $220,000. DRW Securities LLC grew its holdings in Vivos Therapeutics by 179.5% during the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after acquiring an additional 74,441 shares during the period. Finally, Connective Capital Management LLC acquired a new stake in Vivos Therapeutics during the 3rd quarter worth $620,000. Institutional investors own 26.35% of the company’s stock.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.